CND Life Sciences
Develops an accurate, evidence-based tool that helps confirm a diagnosis of synucleinopathy.
Launch date
Employees
Market cap
-
Enterprise valuation
€23m (Public information from Mar 2024)
Phoenix Arizona (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 1.2m | 3.0m | 4.6m |
| % growth | - | 150 % | 53 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $5.0m | Seed | |
* | $2.4m | Grant | |
* | $3.0m | Grant | |
* | N/A | $4.5m Valuation: $25.0m | Seed |
* | N/A | $2.0m Valuation: $25.0m | Seed |
| Total Funding | €19.7m | ||
Related Content
Recent News about CND Life Sciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.